DCPH
Deciphera Pharmaceuticals Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Market Cap: 1.37 Billion
Primary Exchange: NASDAQ
Website: https://www.deciphera.com
Shares Outstanding: 80.8 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.093025520436721
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1321 trading days
From: 2019-12-17 To: 2024-03-07
Lowest Point:
Zai Lab in-licenses ripretinib rights from Deciphera
via: SeekingAlpha at 2019-06-11 04:11:37:000
Deciphera Pharmaceuticals (NASDAQ: DCPH ) inks agreement with Zai Lab (NASDAQ: ZLAB )to commercialize ripretinib in Greater China (mainland China, Hong Kong, Macau and Taiwan). More news on: Zai Lab Limited, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Zai Lab in-licenses ripretinib rights from Deciphera
via: SeekingAlpha at 2019-06-11 04:11:37:000
Deciphera Pharmaceuticals (NASDAQ: DCPH ) inks agreement with Zai Lab (NASDAQ: ZLAB )to commercialize ripretinib in Greater China (mainland China, Hong Kong, Macau and Taiwan). More news on: Zai Lab Limited, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Zai Lab in-licenses ripretinib rights from Deciphera
via: SeekingAlpha at 2019-06-11 04:11:37:000
Deciphera Pharmaceuticals (NASDAQ: DCPH ) inks agreement with Zai Lab (NASDAQ: ZLAB )to commercialize ripretinib in Greater China (mainland China, Hong Kong, Macau and Taiwan). More news on: Zai Lab Limited, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
via: Business Wire at 2019-06-11 03:00:00:000
- Zai Lab to Lead the Development and Commercialization of Ripretinib in Greater China - - Deciphera To Receive $20 Million Upfront Cash Payment, up to $185 Million in Potential Future Milestones and Royalties - - Deciphera Intends to Expand Ripretinib Development Program in Gastr… read more...
Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
via: Business Wire at 2019-06-11 03:00:00:000
- Zai Lab to Lead the Development and Commercialization of Ripretinib in Greater China - - Deciphera To Receive $20 Million Upfront Cash Payment, up to $185 Million in Potential Future Milestones and Royalties - - Deciphera Intends to Expand Ripretinib Development Program in Gastr… read more...
Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
via: Business Wire at 2019-06-11 03:00:00:000
- Zai Lab to Lead the Development and Commercialization of Ripretinib in Greater China - - Deciphera To Receive $20 Million Upfront Cash Payment, up to $185 Million in Potential Future Milestones and Royalties - - Deciphera Intends to Expand Ripretinib Development Program in Gastr… read more...
Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers
via: Business Wire at 2019-06-10 03:00:00:000
- DCC-3116 Selectively Targets ULK Kinase, an Initiating Protein that Activates Autophagy - - Company to Host a Webcast on Tuesday, June 18, 2019 at 8 a.m. ET to Discuss Autophagy Inhibition and the Treatment of Mutant RAS Cancers - Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|